A Phase 2 interventional study of Fulvestrant in Endometrial Carcinoma, sponsored by AstraZeneca. Completed at 9 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-31.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Endometrial Neoplasms by AstraZeneca — 9 open to participants now, 13 under way, 4 of them phase 3. Endometrial Neoplasms · AstraZeneca.
Among the 17 studies in Endometrial Neoplasms by AstraZeneca, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2002, is one of 2 in phase 2, and was the 1st registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
Browse Endometrial Neoplasms studies →9 of the 17 studies in Endometrial Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in United States
Ages 18–130
AstraZeneca · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+ · Women only
AstraZeneca · Sites in Russia
Ages 18+ · Women only
AstraZeneca · Sites in Germany
Ages 18–130 · Women only
By country, each count listing its studies:
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 4
First in 2002; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 457 across the 12 interventional studies, 140 across the 5 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
6 of the studies in Endometrial Neoplasms by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
| NCT07041606AstraZenecaAn Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation | 2027-06-30 |
| NCT06218914AstraZenecaPhase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | 2027-08-30 |
| NCT05123482AstraZenecaA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | 2027-09-29 |
Add all 6 to your calendar (.ics) → With an account.
Among the 17 studies in Endometrial Neoplasms by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.
Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by Assessment of the Clinical Tumour Response After 3 Injections of Fulvestrant
Number of patients with Complete Remission (CR) and Partial Response (PR), as determined by an independent expert panel according to the WHO response criteria.
Time frame: up to 1 year
Time to Progression of Disease (TTP-Time To Progression, for ITT Set)
median TTP
Time frame: ICF (Informed Consent Form completed) to the date of objective progression or death (by any cause in the absence of progression)
Determination (for ITT Set): Median Survival
median overall survival (OS)
Time frame: ICF to the date of death
Determination (All Subjects Treated (AST) Set): Safety and Toxicity by Assessment of the Frequency of Grade I-IV Haematological and Non-haematological Toxicities
number of adverse events
Time frame: ICF to Last Patient Out (LPO)
Evaluation (Patient-reported): Change From Baseline in Health-related Quality of Life (HR-QoL) at 12 Months (12 Visits)
Patient-reported FACT-EN questionaire. Presented is the change from baseline after 12 visits/12 months. The overall total score of 43 single items was transformed to a scale from 0 to 100 (0 = worst level of well-being; 100 = highest level of well-being).
Time frame: ICF (Baseline) up to 12 months (12 visits)
| Milestone | Fulvestrant |
|---|---|
| Started | 35 |
| Completed | 30 |
| Not completed | 5 |
| Withdrew: Patients received fewer than 3 injection | 5 |
Number of patients with Complete Remission (CR) and Partial Response (PR), as determined by an independent expert panel according to the WHO response criteria.
| participants | Fulvestrant |
|---|---|
| Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by Assessment of the Clinical Tumour Response After 3 Injections of Fulvestrant | 5 |
median TTP
| months | Fulvestrant |
|---|---|
| Time to Progression of Disease (TTP-Time To Progression, for ITT Set) | 3.1 (2.6 to 6.5) |
median overall survival (OS)
| months | Fulvestrant |
|---|---|
| Determination (for ITT Set): Median Survival | 16.7 (8.6 to 44.4) |
number of adverse events
| adverse events | Fulvestrant |
|---|---|
| Determination (All Subjects Treated (AST) Set): Safety and Toxicity by Assessment of the Frequency of Grade I-IV Haematological and Non-haematological Toxicities | 169 |
Patient-reported FACT-EN questionaire. Presented is the change from baseline after 12 visits/12 months. The overall total score of 43 single items was transformed to a scale from 0 to 100 (0 = worst level of well-being; 100 = highest level of well-being).
| units on a scale | Fulvestrant |
|---|---|
| Evaluation (Patient-reported): Change From Baseline in Health-related Quality of Life (HR-QoL) at 12 Months (12 Visits) | 6.0 ± 1.3- |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fulvestrant | — | — | — |
| Event | Fulvestrant |
|---|---|
| IleusGastrointestinal disorders | 2/35 |
| TachycardiaCardiac disorders | 1/35 |
| Abdominal painGastrointestinal disorders | 1/35 |
| VomitingGastrointestinal disorders | 1/35 |
| SubileusGastrointestinal disorders | 1/35 |
| General physical health deteriorationGeneral disorders | 1/35 |
| Oedema peripheralGeneral disorders | 1/35 |
| GastroenteritisInfections and infestations | 1/35 |
| Wound infectionInfections and infestations | 1/35 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/35 |
| Event | Fulvestrant |
|---|---|
| NauseaGastrointestinal disorders | 9/35 |
| FatigueGeneral disorders | 8/35 |
| Urinary tract infectionInfections and infestations | 7/35 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/35 |
| Hot flushVascular disorders | 6/35 |
| Abdominal painGastrointestinal disorders | 4/35 |
| ConstipationGastrointestinal disorders | 4/35 |
| DiarrhoeaGastrointestinal disorders | 4/35 |
| Vaginal haemorrhageReproductive system and breast disorders | 4/35 |
| VomitingGastrointestinal disorders | 4/35 |
| Age, Customized(years) | Fulvestrant |
|---|---|
| Median | 69.5 (45 to 83) |
| Sex: Female, Male(Participants) | Fulvestrant |
|---|---|
| Female | 35 |
| Male | 0 |
The record gives a start of Dec 2002, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant